Background-Patients with high anxiety sensitivity (AS) become extremely anxious with heart rate increases, palpitations, and symptoms of psychological arousal. AS predicts panic attacks. In atrial fibrillation (AF), AS correlates with symptom preoccupation and reduced quality of life. We assessed whether AS is associated with outcomes of rhythm-control versus rate-control in congestive heart failure (CHF) patients with AF. 
A nxiety sensitivity (AS) is the fear of bodily sensations associated with anxiety. 1 Sweaty palms, shallow breathing, rapid pulse, and other symptoms accompanying stress can be perceived as relatively benign or as warnings of impending doom. People with higher AS tend to overinterpret and catastrophize in response to such symptoms. AS is a relatively constant personality factor. It is distinct from anxiety itself, which fluctuates with events. 2 Most research on AS has focused on panic disorder. 3 Panic disorder patients have higher scores than normal individuals on AS measures, and people with higher AS are more likely to have panic attacks. 4 We previously reported that coronary artery disease patients who experience panic attacks provoked by CO 2 inhalation show significantly greater reversible myocardial perfusion defects than those who do not panic, 5 suggesting that AS might be associated with prognosis.
Editorial see p 307 Clinical Perspective on p 330
In atrial fibrillation (AF) patients, AS has been explored as a cross-sectional correlate of lower quality of life and greater symptom severity and preoccupation. 6 Indeed, individuals with higher AS are more aware of their heartbeats and heart rate reactivity, 7 but the potential prognostic importance of AS has not been explored. In the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial, 8 patients with AF and CHF responded to the Anxiety Sensitivity Inventory (ASI) 9 before random assignment to rate-control versus rhythm-control strategies. They were followed for at least 2 years. Because individuals with higher AS tend to be more preoccupied with AF symptoms, we explored whether the psychological/physiological correlates of AF, and/or treatments influencing it, might also vary with AS.
Methods
The methodology of the AF-CHF trial was reported previously. 8 Between May 2001 and June 2005, 1376 AF patients with CHF from 123 sites in 10 countries were randomly assigned to AF treatment strategies focusing on rhythm-or rate-control. Institutional review boards at each site approved the protocol. Patients were eligible if they had ECG-documented AF in the past 6 months and a left ventricular ejection fraction (LVEF) Յ35% with symptomatic CHF or hospitalization for CHF during 6 months before baseline. Patients were excluded for contraindications to either treatment arm, life expectancy Ͻ1 year, anticipated cardiac transplant within 6 months, persistent AF for 12 months, decompensated heart failure within 48 hours before random assignment, other indications for antiarrhythmic agents, second-or third-degree atrioventricular block, previous atrioventricular node ablation, long-QT syndrome, renal failure (dialysis), were Ͻ18 years old, or were women of child-bearing potential not using contraceptives.
CHF treatment approaches were the same in both study arms, including recommendations for anticoagulants, either angiotensinconverting enzyme (ACE) inhibitors or angiotensin II receptor antagonists, and the highest tolerable dose of ␤-blockers. Pacemakers, implantable defibrillators, and ventricular resynchronization were used if indicated. Patients randomly assigned to rhythm-control were treated with antiarrhythmic medication (primarily amiodarone) and electric cardioversion for AF recurrences. In rate-control, patients were prescribed ␤-blockers and digoxin titrated to keep resting heart rate Ͻ80 beats per minute during AF and Ͻ110 during 6-minute walk tests.
Assessment of AS
Patients speaking English, French, Portuguese, Spanish, or Dutch completed the ASI 9 before random assignment. The ASI is the most commonly used measure of AS and has well-established reliability and validity. 4 It includes 16 self-report items (for example, "it scares me when my heart beats rapidly"; "it is important for me not to appear nervous") with 5-point agreement scales ranging from "very little" (0) to "very much." 4 Total scores range from 0 to 64. Higher scores reflect higher AS. The ASI is usually analyzed as a continuous measure. 2 Because there is no established cut-point to identify individuals with high ASI scores, to improve clinical interpretability of continuous data, the upper quartile of the sample was prespecified as defining high scores.
Outcome Assessment
Clinical assessments occurred at 3 weeks and 4 months and then every 4 months for 4 years. After that, evaluations occurred every 6 months. A committee blinded to treatment group and ASI score rated causes of death. The primary outcome was cardiovascular death (as in the overall trial).
Statistics
PASW Statistics, release 18.0.0 (SPSS Inc, Chicago, IL) was used for analyses. Statistical tests were 2-tailed, using PՅ0.05 to determine significance. Comparisons of baseline characteristics between patients who did and did not complete the ASI, and between those with high (Ն33) versus lower ASI scores were conducted using 2 tests for categorical variables and t tests for continuous measures. To assess whether background differences associated with high versus lower ASI scores differed between rhythm-and rate-control groups, logistic regression analysis was used to evaluate interactions between treatment group and dichotomized ASI scores for dichotomous background variables. Analysis of variance was used to assess interactions with continuous background measures.
After verification of proportionality assumptions, the prognostic importance of randomly assigned treatment group and AS were assessed using Cox proportional hazards regression analysis. Probability values for interactions between treatment and standardized ASI scores and between treatment and the dichotomized variable of high versus lower ASI scores were assessed using the likelihood ratio test to evaluate interaction terms by adding them to models containing the primary variables. Patients lost to follow-up or receiving a heart transplant were censored on the last day known to be alive or transplant-free.
Covariates for the AF-CHF psychosocial substudy were not prespecified, but the protocol for the overall AF-CHF trial 8 identified the following baseline characteristics for statistical adjustment based on their potential impact on cardiovascular mortality: age, sex, LVEF, New York Heart Association (NYHA) functional class, hypertension, diabetes, implantable cardioverter-defibrillator, time since first AF diagnosis, creatinine level, and use of ␤-blockers, ACE inhibitors, and oral anticoagulants. Because our previous AF-CHF publication demonstrated a prognostic importance for depression symptoms and marital status, 10 the Beck Depression Inventory, version 2 (BDI-II) 11 and marital status were also included in the current multivariable models.
To evaluate whether the component therapies included in the rhythm-and rate-control strategies varied according to AS, logistic regression was used to compare specific therapies received at 1 year by high and lower ASI patients assigned to rhythm and rate control. To explore whether the benefit from component therapies varied according to AS, Cox proportional hazards regression analysis was used to assess the long-term prognostic importance of AS, component therapies at 1 year, and their interactions in 1-year survivors.
Results
There were 1238 AF-CHF study participants from sites with native language versions of the ASI. Of these, 933 (75.4%) completed the ASI. Noncompleters were older, less likely to be white, and more likely to have NYHA functional class Ͼ2, hypertension, AF on the baseline ECG, prior hospitalizations for AF, and hospitalizations for CHF in the preceding 6 months. As in the AF-CHF depression analyses, 10 this pattern of differences did not differ between rhythm-and rate-control groups. Patients who were transplanted (nϭ9; Pϭ0.52) or lost to follow-up (nϭ35; Pϭ0.30) did not differ in mean ASI scores from others.
Patients ranged in age from 24 to 92 years (mean, 66.0; SD, 11.2), with 17.7% women. A total of 470 were randomly assigned to rhythm-control and 463 to rate-control. The mean ASI score was 23.3Ϯ13.0 (range, 0 -58; median, 22.0). There was no treatment group difference in mean ASI scores (rhythm-control, 22.9; rate-control, 23.8; Pϭ0.25), or in the proportion with high ASI scores (23.0% of rhythm-control patients; 27.0% rate-control; Pϭ0. 16) . Table 1 shows baseline characteristics according to dichotomized ASI score. Participants with high ASI scores were more likely to be women, younger, and nonwhite and had less education than patients with lower scores. They also had lower creatinine levels, were more likely to have had previous antiarrhythmic treatment, less likely to have NYHA functional class Ͼ2, and less likely to be in AF at baseline. Patients with high ASI scores were more likely to be taking diuretics and aldosterone antagonists. Finally, patients with high ASI scores had significantly higher levels of depression symptoms as measured by the BDI-II.
During a mean follow-up of 39Ϯ18 months (range, 24 -74 months for survivors), 287 patients died, including 232 from cardiovascular causes. Paralleling overall study results, 8 there was no difference in time to cardiovascular death between those assigned to rhythm-versus rate-control treatment strategies (see Table 2 ). There was also no significant main effect of AS, but there was a significant interaction between randomly assigned treatment group and AS in time to cardiovascular death. This is illustrated in the Figure, using the dichotomized high versus lower ASI groups. In patients with lower ASI scores, there was no difference in prognosis between the rhythm-and rate-control treatment strategies. However, in patients with scores in the upper quartile, there was a significant benefit of rhythm-control in comparison to rate-control. Table 3 for characteristics in multivariable models; tests for interactions were also adjusted for treatment and AS. †There were 9 heart transplants, 55 noncardiovascular deaths, and 35 losses to follow-up. All were censored on the last day known to be living or transplant free. 
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An alternate way to describe the significant interaction between AS and randomly assigned treatment group involves comparing the association between AS and cardiovascular death in the rhythm-versus rate-control groups. Although increasing AS (standardized ASI score) was associated with significant increases in the hazards ratio for cardiovascular mortality in the rate-control group, there was little evidence of a relationship in those randomly assigned to rhythmcontrol (Table 2) .
One potential explanation for the apparently better prognosis with rhythm-control in the high AS patients is that random assignment was not stratified according to AS leading to AS-related differences in prognostically important baseline factors. These differences could have varied between randomly assigned treatment groups. However, the pattern of measured baseline factors associated with AS was very similar in patients assigned to rhythm-and rate-control, with only 2 background variables showing significant interactions between treatment group and AS: hypertension and primary classification of AF (paroxysmal versus persistent). The background data in Table 1 are provided separately according to randomly assigned treatment group only for these characteristics. However, neither hypertension nor AF type was significantly related to cardiovascular mortality overall or in 2-way interactions with treatment strategy or AS or in 3-way interaction with treatment strategy and AS (all PϾ0.18). In addition, adjustment for preselected covariates, including depression symptoms and marital status (Table 2) , did not alter the observed pattern of main effects and interactions.
The multivariable model appears in Table 3 .
Another possible explanation for the interaction between treatment group and AS is that the component therapies provided to the randomly assigned treatment groups may have varied with AS. It would not be surprising if patients who were very focused on their bodily symptoms and were rendered anxious by them received different therapy types within protocol parameters. To explore this, we examined whether the specific components of medical therapy included in the rate-and rhythm-control strategies were applied with similar frequencies at one year in the high and lower AS groups ( Table 4 ). The 1-year point was selected to allow for titration of medical therapy. The overall interaction of treatment group by AS continued to be significantly associated with subsequent cardiovascular mortality when the sample was limited to 1-year survivors (Pϭ0.002 for interaction involving dichotomized ASI; Pϭ0.006 for interaction involving standardized ASI score).
The only AS-related difference in the 1-year application of specific study therapies was a higher proportion of ␤-blocker use in high versus lower AS patients. However, the interaction between AS and randomly assigned treatment group for 1-year cardiovascular mortality remained significant after control for ␤-blocker use at 1 year (PϽ0.001 for interaction involving dichotomized ASI and for interaction involving standardized ASI score). Thus, it is unlikely that differential application of the component therapies included in the randomly assigned treatment strategies accounted for the better prognosis of high AS patients in rhythm-control. Further, there was only 1 significant interaction between a specific therapy received at 1 year and AS (Table 4 ). In rate-control, high AS patients were significantly more likely to be cardioverted during the first year than those with lower ASI scores. In those assigned to rhythm-control, the relationship between AS and cardioversion rates was not significant. As previously reported, 12 there was a higher proportion of crossover from rhythm-control to rate-control (mostly due to inability to maintain sinus rhythm) than vice versa, but crossover occurred in approximately the same proportion of high and lower AS patients.
Another possible explanation for the interaction between AS and randomly assigned treatment group is that some aspects of the treatment protocol differed in impact according to AS. Recognizing that the specific therapies received at 1 year were not randomly assigned, to gain some insight into the issue of potential AS-related therapy impact differences, we conducted exploratory analyses of the association between the therapies received at 1 year and long-term cardiovascular mortality (Table 5) . High AS patients had significantly better long-term prognosis when treated with an antiarrhythmic medication at 1 year (mostly, amiodarone). In the lower AS group, 1-year antiarrhythmic use was not related to long-term prognosis. Sinus rhythm at 1 year was also significantly more strongly associated with prognosis in the high AS group than in those with lower AS, but this difference was somewhat attenuated by covariate adjustment. Although there was a significant link between heart rate reduction and prognosis in the high AS group and a nonsignificant relationship in the lower AS patients, the interaction between heart rate reduction and AS was not significant. Similarly, the interaction of having a pacemaker inserted by 1 year and AS did not reach significance, but in the lower AS group those with pacemakers showed a significantly greater hazard ratio for cardiovascular mortality than those without, with little evidence of a relationship in the high AS group.
Discussion
It has long been thought that maintenance of sinus rhythm should have positive prognostic consequences for AF patients, especially those at added risk because of CHF, but clinical trials have not supported this hypothesis. Conjecture has focused on the negative pleotropic effects and low level of efficacy of existing antiarrhythmic medications. 13 In this AF-CHF substudy of patients whose personalities were characterized by high AS, the tendency to fear and catastrophize in response to bodily symptoms of anxiety derived a prognostic benefit from rhythm-control compared with ratecontrol. We also observed that sinus rhythm at 1 year was significantly more important for long-term cardiovascular prognosis in patients with high AS compared with lower AS. A similar but nonsignificant pattern occurred for lower resting heart rate. Given amiodarone's multiple electrophysiological effects, 14 the beneficial impact of maintaining sinus rhythm cannot be dissociated from the influence of a lower resting heart rate. However, with what is known about AS, it is likely that control of heart rate and maintenance of sinus rhythm were both important.
Interestingly, whereas AS did not have any overall relationship with cardiovascular mortality, it was associated with an increased hazard ratio in patients randomly assigned to rate-control. This increase in hazard was not apparent among patients in the rhythm-control group, most of whom were treated with amiodarone or another antiarrhythmic. This is reminiscent of subgroup results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT) in post-myocardial infarction patients with frequent ventricular premature depolarizations. 15 Investigators reported that baseline depression symptoms (measured with the original BDI-I) had a negative impact on sudden cardiac death in the placebo group but had little impact in those receiving amiodarone. As reported previously, 10 in the AF-CHF trial there was no significant interaction in outcomes between depression and random assignment to rhythm-control versus rate-control. However, we administered the BDI-II, and there are multiple differences between the CAMIAT sample and the AF-CHF patients. It is intriguing, but perhaps coincidental, that although depression's impact was not moderated by amiodarone treatment in AF-CHF patients, the impact of another psychological construct, AS, did differ according to random assignment to a treatment strategy including amiodarone. Arrhythmic mechanisms may be important for understanding the prognostic importance of a variety of psychological factors.
In AF-CHF, the mean ASI score (23.3Ϯ13.0) was lower than that reported for panic disorder patients (mean of 36.4 over 27 studies), 16 but it was higher than for normal subjects (17.8Ϯ8.8), 17 and for AF patients without CHF (19.0Ϯ10.9). 6 It may be useful to consider a cognitive theory of AF similar to the cognitive theory of panic disorder 3 in which AS is central in terms of both psychological and physiological mechanisms. In patients with AF and CHF who have high AS, heightened awareness of AF symptoms including palpitations and heart rate changes may increase fear, augmenting physiological sensations and thoughts of catastrophe, increasing sympathetic arousal, catecholamine levels, and heart rate in a vicious cycle, potentially increasing arrhythmic risk. In such patients, the benefits of preventing ventricular arrhythmias and lowering heart rate may be particularly important and may outweigh potential negative pleiotropic effects of amiodarone treatment. 18 Results may also have behavioral explanations. Hypochondriasis and excessive health anxiety have been linked to higher AS. 16 We observed that high AS patients randomly assigned to rate-control were significantly more likely to be cardioverted at least once during the first year than patients with lower AS scores. Perhaps high AS patients' reports of AF symptoms were severe or frequent enough that their physicians chose to restore sinus rhythm electrically despite the patients' assignment to rate-control.
It has long been known that ␤-blockers can decrease performance anxiety and at least some of its physiological effects. It has also been suggested that patients with increased AS might benefit from ␤-blockade, 19 but the literature on ␤-blockers' impact on anxiety/anxiety disorders is inconsistent. Although a higher level of ␤-blocker prescription among ASI indicates Anxiety Sensitivity Inventory; HR, hazard ratio; and CI, confidence interval. *HRs provided for high and lower ASI groups regardless of significance of interaction. †Covariate adjusted only for significant interactions or comparisons with significance in at least 1 of 2 ASI groups; multivariable models included baseline characteristics from Table 3 ; interactions adjusted for ASI and the therapy/result being evaluated rather than assignment to rhythm-control versus rate-control. ‡nϭ789; high ASI, nϭ199; lower ASI, nϭ590.
high AS patients in the rhythm-control group or a higher impact of ␤-blockers among them could potentially have explained study outcomes, neither of these hypotheses was supported by the data.
Limitations
Because this is a secondary analysis of a clinical trial, there are important caveats. Random assignment was not stratified according to AS. We do not know the extent to which prognostic differences between rhythm-and rate-control were due to AS per se or to other unmeasured variables associated with AS (including anxiety) or their fluctuations over time.
Statistical adjustment for baseline characteristics cannot make up for this problem. In short, as in all subgroup analyses, causal inferences cannot be drawn, and results must be interpreted as exploratory. However, these data illustrate the potential importance of individual patient factors in treatment outcomes. It is hoped that they will stimulate additional research into these complex issues.
The sample included only 17.7% women, reflecting the overall AF-CHF trial (18.5% women), 8 and is a limitation to the generalizability of results. Due to the number and geographic diversity of study sites, structured psychiatric interviews were not conducted. We do not know the extent of comorbid panic disorder among participants. AS and depression symptoms were measured only at baseline, and we do not know how changes in these factors may have influenced outcomes. In addition, the AF-CHF trial collected no data on use of anxiolytics, antidepressants, or any selftreatments for anxiety or depression including alcohol or herbal products. However, at least 1 trial has failed to show any benefit of antidepressant treatment on prognosis in CHF patients. 20 All participants volunteered to participate in a clinical trial and to complete the ASI, with noncompleters being older and somewhat sicker than those who took part. We do not know the extent to which results pertain outside this environment.
Conclusions
This is the first study to suggest that a measure of personality may be important in tailoring treatment selection for cardiac patients. Better prognosis was observed with rhythm-control versus rate-control in patients with high AS. Results support the notion that AF treatment "should focus more on the patient than on the ECG" 21 and suggest several areas for further study including replication in other AF samples; longitudinal exploration of the cardiovascular prognostic importance of AS and changes in AS and depression, as well as subsequent reports of AF symptoms; assessing the degree to which ASI scores may help identify patients with silent AF; exploring the prevalence of panic disorder and panic symptoms in AF patients; and evaluating approaches for reducing AS including cognitive-behavioral therapy, 22 exercise, 23 and possibly psychotropic medications with the aim of reducing the frequency of AF episodes in susceptible individuals.
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